HC Wainwright Issues Negative Forecast for MNPR Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for shares of Monopar Therapeutics in a research report issued on Tuesday, April 1st. HC Wainwright analyst S. Lee now expects that the company will earn ($0.44) per share for the quarter, down from their previous forecast of ($0.35). HC Wainwright has a "Buy" rating and a $40.00 price objective on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Monopar Therapeutics' Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.89) EPS, FY2026 earnings at ($1.68) EPS, FY2027 earnings at $0.72 EPS and FY2028 earnings at $2.08 EPS.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its earnings results on Monday, March 31st. The company reported ($2.23) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($1.87).

MNPR has been the topic of several other research reports. Jones Trading reaffirmed a "hold" rating on shares of Monopar Therapeutics in a report on Wednesday, April 2nd. Piper Sandler restated an "overweight" rating and set a $76.00 price target on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, Monopar Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $44.00.

Remove Ads

Monopar Therapeutics Trading Down 4.1 %

Shares of NASDAQ MNPR traded down $1.18 during mid-day trading on Thursday, reaching $27.71. The company had a trading volume of 8,296 shares, compared to its average volume of 357,257. The firm has a 50 day simple moving average of $38.20 and a two-hundred day simple moving average of $25.35. Monopar Therapeutics has a 52-week low of $1.72 and a 52-week high of $54.30. The stock has a market cap of $169.40 million, a P/E ratio of -14.11 and a beta of 1.01.

Hedge Funds Weigh In On Monopar Therapeutics

Large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. acquired a new position in shares of Monopar Therapeutics during the fourth quarter worth about $45,000. Geode Capital Management LLC raised its stake in shares of Monopar Therapeutics by 174.4% during the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock worth $849,000 after buying an additional 24,530 shares in the last quarter. ADAR1 Capital Management LLC purchased a new position in shares of Monopar Therapeutics during the 4th quarter worth approximately $2,861,000. Point72 Asset Management L.P. purchased a new stake in shares of Monopar Therapeutics in the fourth quarter valued at approximately $3,694,000. Finally, RA Capital Management L.P. acquired a new position in Monopar Therapeutics during the fourth quarter worth $11,247,000. Hedge funds and other institutional investors own 1.83% of the company's stock.

Insider Transactions at Monopar Therapeutics

In related news, major shareholder Tactic Pharma Llc sold 33,334 shares of the stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the completion of the sale, the insider now directly owns 822,255 shares of the company's stock, valued at $28,778,925. This trade represents a 3.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 34.90% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.